AIM
CSTL icon

Arcadia Investment Management’s Castle Biosciences CSTL Stock Holding History

Arcadia Investment Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-904
Closed -$18.1K – 258
2025
Q1 		$18.1K Hold
904
– – ﹤0.01% 229
2024
Q4 		$24.1K Buy
+904
New +$27.5K ﹤0.01% 248
2024
Q3 		– Sell
-522
Closed -$11.4K – 270
2024
Q2 		$11.4K Hold
522
– – ﹤0.01% 271
2024
Q1 		$11.6K Hold
522
– – ﹤0.01% 271
2023
Q4 		$11.3K Buy
+522
New +$9.19K ﹤0.01% 282

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Arcadia Investment Management's CSTL Position: Q2 2025 in Review

Arcadia Investment Management sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 904 shares — an estimated $18.1K sold.

Arcadia Investment Management first reported a position in CSTL in Q4 2023 and held it in 5 quarters. The position peaked at $24.1K in Q4 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Arcadia Investment Management reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Arcadia Investment Management sold 904 Castle Biosciences shares in Q2 2025, an estimated $18.1K.
  • Arcadia Investment Management first reported a position in Castle Biosciences in Q4 2023 and held it in 5 quarters.
  • Arcadia Investment Management's Castle Biosciences position peaked at $24.1K in Q4 2024.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Arcadia Investment Management's 13F filing for Q2 2025, filed 8 Aug 2025.